RestructuringMay 26, 2026, 06:17 AM
Takeda Records JPY 129.3B Impairment, JPY 70.8B Restructuring Costs
AI Summary
Takeda Pharmaceutical disclosed JPY 129,266 million in impairment losses on intangible assets, including JPY 58,173 million for a cell therapy platform and JPY 31,877 million for ALUNBRIG due to reduced sales forecasts. The company also recorded JPY 70,818 million in restructuring expenses from an efficiency program. Additionally, Takeda acquired 11,824 thousand common shares for JPY 49,978 million. The filing detailed accounting policies, estimates for provisions, and ongoing legal proceedings.
Key Highlights
- Impairment losses on intangible assets totaled JPY 129,266 million.
- JPY 58,173 million impairment related to gamma delta T-cell therapy platform.
- JPY 31,877 million impairment for ALUNBRIG due to reduced sales forecasts.
- Restructuring expenses were JPY 70,818 million from an enterprise-wide efficiency program.
- Other operating expenses included JPY 50,984 million for pre-launch inventories valuation reserve.
- Takeda acquired 11,824 thousand common shares for JPY 49,978 million.
- Aggregate provisions for legal and other disputes were JPY 13,204 million.
- Provisions for contractual and statutory rebates payable were JPY 291,232 million.
Price Impact
More from TAK